Octreotide inhibits the enterochromaffin-like cell but not peroxisome proliferator-induced hypergastrinemia

I Bakke, A K Sandvik and H L Waldum
Department of Physiology and Biomedical Engineering, Norwegian University of Science and Technology, and Department of Medicine, University Hospital of Trondheim, Trondheim, Norway

(Requests for offprints should be addressed to I Bakke, Department of Physiology and Biomedical Engineering, Faculty of Medicine, Norwegian University of Science and Technology, N-7489 Trondheim, Norway; Email: Ingunn.Bakke@medisin.ntnu.no)

ABSTRACT
The peroxisome proliferator ciprofibrate induces hypergastrinemia and as a consequence, enterochromaffin-like (ECL) cell hyperplasia. The mechanism for the gastrin cell stimulation is unknown. The somatostatin analog octreotide LAR (long-acting release) was used to see if the stimulating effect of ciprofibrate could be attenuated. Female Fischer rats were dosed with ciprofibrate (50 mg/kg body weight per day) alone or combined with octreotide LAR (10 mg/30 days) for 60 days. Plasma gastrin and histamine, gastric endocrine cell densities and mRNA abundances were measured. Ciprofibrate increased gastrin mRNA abundance ($P<0.05$), gastrin cell number ($P<0.001$) and cell area ($P<0.01$), and induced hypergastrinemia ($P<0.001$). These rats had profound ECL cell hyperplasia, confirmed by an increase in chromogranin A (CgA) and histidine decarboxylase (HDC) mRNA, density of neuroendocrine and ECL cells and plasma histamine levels (all $P<0.001$). Octreotide LAR did not affect ciprofibrate stimulation of gastrin cells, but all parameters of ECL cell hyperplasia were reduced ($P<0.001$). Octreotide LAR also significantly inhibited basal ECL cell function and growth. Ciprofibrate stimulates gastrin cell activity by a mechanism unaffected by octreotide, but octreotide does inhibit basal and gastrin-stimulated ECL cell function and growth.

Journal of Molecular Endocrinology (2000) 25, 109–119

INTRODUCTION
The peroxisome proliferator group of substances have a tumorigenic effect on the liver, inducing hyperplasia and hepatocellular carcinomas (Issemann & Green 1990). The exact mechanism for the neoplastic effect is not known, but it is non-genotoxic (O’Brien et al. 1996). Some of these substances, like ciprofibrate and other fibrates (phenyoxisobutyrate derivatives), also induce hypergastrinemia under sustained exposure (Eason et al. 1988c, Spencer et al. 1989). Gastrin stimulates function of the enterochromaffin-like (ECL) cell and long-term hypergastrinemia causes ECL cell hyperplasia and carcinoid (Ryberg et al. 1989).

The mechanism for the stimulating effect of fibrates on the gastrin-producing G cell is also unknown. Previously, it was claimed that the hypergastrinemia was secondary to reduced gastric acidity (Eason et al. 1988a,b), similar to treatment with proton pump inhibitors and histamine $H_2$ blockers (Ryberg et al. 1989). However, in recent studies, we have shown that ciprofibrate induces hypergastrinemia without reducing gastric acidity, and that high doses even decrease gastric pH, probably because of the increased stimulatory effect of circulating gastrin (Martinsen et al. 1996). We have also shown that the hypergastrinemic effect of ciprofibrate begins later (14 days) than the effect of gastric acid inhibitors (Ryberg et al. 1989) and that co-administration with omeprazole potentiates the hypergastrinemic effect (Hammer et al. 1998). Thus, ciprofibrate causes hypergastrinemia through a mechanism independent of gastric pH. Ciprofibrate not only increases gastrin mRNA abundance and raises serum gastrin concentration, but also tends to increase expression of somatostatin in the antrum (Hammer et al. 1998, Waldum et al. 1998). This is different from the reciprocal relationship that normally exists between gastrin and somatostatin in the antrum (Lundell et al. 1988, Wu et al. 1991). Similar dual increase of these antral peptides...

Somatostatin is widely distributed in the body, suppressing biological events like hormone release and cell proliferation (Lamberts et al. 1991). In the stomach, D cells are located in proximity to their target cells, and exert a restraint on the secretion of histamine and gastrin (Saffouri et al. 1980, Sandvik & Waldum 1988, Karnik et al. 1989). Receptors for somatostatin are found on ECL and G cells (Borin et al. 1996, Zaki et al. 1996). Long-acting somatostatin analogs have been developed for therapeutic use and are especially useful in patients with secretory neuroendocrine tumors (Lamberts et al. 1991). Octreotide is effective in controlling hypergastrinemia and in inhibiting both fundic endocrine preneoplastic growth and tumor growth in the stomach (Modlin et al. 1992, Bordi et al. 1993, D’Adda et al. 1996).

The aim of this study was to further assess the so far unknown and maybe novel mechanism for the effect of ciprofibrate on the endocrine cells in the rat stomach, by looking at both changes in morphology of the antral and oxyntic mucosa and the mRNA expression of secretory products. Furthermore, we wanted to see if the somatostatin analog octreotide LAR (long-acting release) could attenuate these effects of ciprofibrate.

MATERIALS AND METHODS

Materials

The drugs used were ciprofibrate (2-[(4(6-2,2 dichlorocyclopropyl)phenoloxyl]-2-methyl propanoic acid) (Modalim; Sanofi-Synthelabo, Alnwick, Northumberland, UK) and octreotide LAR, a generous gift from Novartis Pharma AG (Basel, Switzerland). Fischer rats were purchased from Mollegaard’s Breeding Center (Skensved, Denmark). Immunohistochemistry was done with a avidin-biotin-complex (ABC) technique, using a Vectastain peroxidase-rabbit-ABC-kit (PK-4001) and a peroxidase substrate-kit (AEC SK4200) from Vector Laboratories, Inc. (Burlingame, CA, USA). Antisera used were: rabbit polyclonal anti-histidine decarboxylase (HDC) (cat. no. B260-1; Euro-diagnostics, Malmö, Sweden), rabbit polyclonal anti-chromogranin A (CgA) (cat. no. 20086; INCSTAR, Stillwater, MN, USA), rabbit polyclonal anti-human somatostatin (cat. no. A566) and rabbit polyclonal anti-human gastrin (cat. no. A568) both from DAKO A/S (Glostrup, Denmark) and mouse monoclonal anti-β-H+/K+-ATPase (cat. no. MA3–923; Affinity BioReagents, Inc., Golden, CO, USA). Histamine RIA kits were purchased from Immunotech (Marseille, France), 32P-labeled nucleotides from Amersham International (Amersham, Bucks, UK), nylon membranes from Boehringer Mannheim (Mannheim, Germany) and NICK columns from Pharmacia Biotech AB (Uppsala, Sweden).

Study design

The study was approved by the animal welfare committee of the University Hospital of Trondheim. Female Fischer rats (200–250 g) were assigned to four groups (I–IV) of 12, 14, 12 and 12 rats respectively, and housed in wire-bottom cages at 20 °C with a relative humidity of 40–45%, a 12 h light:12 h darkness cycle and free access to commercial rat chow and water. All groups were given 1 ml tap water with or without ciprofibrate (50 mg/kg body weight) once daily by gastric intubation. Octreotide LAR or placebo drug (10 mg) was dissolved in 1 ml of the supplied vehicle, and 0·5 ml was injected i.m. in both thighs on day 1 and day 28 of the study period. Group I (control) was given tap water and placebo drug, group II ciprofibrate and placebo drug, group III tap water and octreotide LAR and group IV both ciprofibrate and octreotide LAR. The purpose of this study was to examine the mechanisms of both ciprofibrate and octreotide action on endocrine cells in antral and oxyntic mucosa. Therefore, the doses used were not clinically matched, but instead set very high to ensure maximal effects of the drugs. The depot formulation of octreotide, octreotide LAR, was used because of its convenience in long-term studies, reducing the number of injections and giving a more stable plasma level of the somatostatin analog during the study period. Initially the rats were given 80 mg/kg ciprofibrate, but because of weight loss in some of the rats after 1 week, the dose was reduced to 50 mg/kg. One rat in group II died after 2 weeks. After injection of octreotide LAR/placebo on day 28, further weight loss in some rats made it necessary to stop the administration of drug to these rats for 6–12 days.

The rats were weighed at the start and weekly throughout the study. Blood was taken from the femoral vein of anesthetized (0·3 ml/100 g body weight of 2·5 mg/ml fluanison, 0·05 mg/ml fentanyl and 1·25 mg/ml midazolam) rats on day 1, day 21 and day 60. Plasma was frozen for later determination of histamine and gastrin by RIA (Kleveland et al. 1985, Waldum et al. 1989). At the end of the study, the rats were anesthetized and killed by decapitation. The stomachs were immediately
removed, opened at the major curvature and rinsed in saline. Biopsies were taken from the oxyntic and antral mucosa and fixed in 4% buffered formaldehyde or homogenized for RNA extraction. The homogenates were immediately frozen at \(-80^\circ\text{C}\).

**Immunohistochemical procedures**

Fixed tissue specimens were dehydrated, embedded in paraffin and cut perpendicular to the mucosal surface in 5 µm thick sections. Before staining, the sections were dewaxed, rehydrated and treated with 3% H\(_2\)O\(_2\) for 10 min. Corpus sections were incubated overnight at \(4^\circ\text{C}\) with primary antibody to CgA (1:500 dilution), HDC (1:3000 dilution) and \(\text{H}^+ / \text{K}^+\text{ATPase}\) (1:3000 dilution). The antral sections were incubated overnight at \(4^\circ\text{C}\) with primary antibody to CgA (1:500 dilution), gastrin (1:700 dilution) and somatostatin (1:800 dilution).

mRNA analysis

Tissue biopsies were homogenized using a rotating-knife homogenizer (Ultra-Turrax, Janke & Kunkel, IKA-Labortechnik, Staufen, Germany) in a denaturing buffer (1 ml/100 mg tissue) containing 4 M guanidinium isothiocyanate, 25 mM sodium acetate (pH 6.4) and 0·84% (v/v) β-mercaptoethanol. Total RNA was isolated by ultracentrifugation of the homogenates through a cushion of 5·7 M cesium chloride and precipitated with ethanol.

HDC, CgA, somatostatin, gastrin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) probes were made as outlined previously (Angelsen et al. 1997, Sandvik et al. 1997, Hammer et al. 1998). 18S RNA was amplified from total RNA by PCR, using primers corresponding to the 1236–1253 and 1792–1809 stretches of the rat 18S RNA sequence (Chan et al. 1984) after reverse transcription with the 1792–1809 primer. The product was cloned into the pCRII vector (Invitrogen, San Diego, CA, USA) and verified by sequencing.

Plasmids were linearized, and antisense RNA probes labeled with \(^{32}\text{P}\) by transcription according to standard protocols and purified on NICK columns.

Total RNA (20 µg/well) was electrophoresed in 1% agarose-formaldehyde gels, electrobotted onto nylon membranes and crosslinked by UV irradiation. Membranes were prehybridized for 4 h at 65 °C in 5 × saline-sodium phosphate EDTA (SSPE) buffer (1 × SSPE is 0·18 M NaCl, 10 mM NaH\(_2\)PO\(_4\) and 1 mM EDTA, pH 7·4), with 50% deionized formamide, 5 × Denhardt’s solution (0·1% BSA, polyvinylpyrrolidone, and Ficoll 400) and 0·5% SDS. Hybridization was done in the same solution with RNA probe (2 × 10\(^8\) c.p.m./ml) for 18 h, and thereafter the membranes were washed twice with 2 × SSPE containing 0·1% SDS for 20 min at room temperature and once in 0·1 × SSPE with 0·1% SDS at 65 °C. Membranes were exposed to a storage phosphor screen for 24 h, scanned on a PhosphorImager (Molecular Dynamics, Sevenoaks, Kent, UK) and quantified using ImageQuant software (Molecular Dynamics). Stripping between hybridizations was done with boiling 0·1% SDS.

**Data analysis and presentation**

Changes in morphology and mRNA expression were examined in five rats from each group. The mRNA values are expressed as percent of controls (group I). Estimations of mRNA sizes were made with reference to the positions of 18S and 28S ribosomal RNAs. The mRNA abundances were normalized to 18S values, and GAPDH abundance was used as a control. The numerical densities of the cells are expressed as the mean number ± s.e.m. of positive cells/mucosa area in each group. The immunoreactive areas of the different cell types are expressed as the mean positive area ± s.e.m. of measurements done at the start, after 21 days and at the end (60 days). Statistical evaluations between three or more groups were done with a one-way ANOVA and Bonferroni’s post-hoc test. Comparisons between two groups were done with an unpaired t-test, and for all evaluations \(P > 0.05\) was considered non-significant.

**RESULTS**

Plasma gastrin and histamine concentrations

Changes in plasma gastrin during the study period (days 0, 21 and 60) are summarized in Fig. 1A. In...
respectively. In group II, dosed with cipro
brate (group II), gastrin mRNA abundance in group II (269 ± 25% of basal) and HDC (527 ± 13% of basal, P < 0.01) compared with group II 21 days). The abundances of GAPDH mRNA were unchanged in all groups compared with control.

Effects on gene expression in oxyntic mucosa
The effects on gene expression in the oxyntic mucosa are summarized in Figs 3 and 4. Ciprofibrate increased gastrin mRNA abundance in group II (209 ± 54% of basal, P < 0.05 vs control), receiving only ciprofibrate, and in group IV (314 ± 27% of basal, P < 0.01 vs control), receiving both octreotide LAR and ciprofibrate. Gastrin mRNA was also increased in group III, receiving only octreotide LAR, (179 ± 17% of basal, P < 0.01). The somatostatin mRNA level (109 ± 13% of basal) in group II was similar to that in the control group, in spite of the increase in gastrin mRNA. This effect was reversed in the group (IV) receiving both octreotide LAR and ciprofibrate, resulting in a reduced somatostatin mRNA abundance (55 ± 5% of basal) compared with the control group (I) (P < 0.05) and with group II (P < 0.01). In group III, given only octreotide LAR, both somatostatin (40 ± 4% of basal) and CgA (49 ± 6% of basal) mRNA levels were significantly attenuated, compared with controls (group I) (P < 0.01). The abundances of GAPDH mRNA were unchanged in all groups compared with control.

Effects on gene expression in antral mucosa
The effects on gene expression in antral mucosa are summarized in Figs 2 and 3. Ciprofibrate increased gastrin mRNA abundance in group II (209 ± 54% of basal, P < 0.05 vs control), receiving only ciprofibrate, and in group IV (314 ± 27% of basal, P < 0.01 vs control), receiving both octreotide LAR and ciprofibrate. Gastrin mRNA was also increased in group III, receiving only octreotide LAR, (179 ± 17% of basal, P < 0.01). The somatostatin mRNA level (109 ± 13% of basal) in group II was similar to that in the control group, in spite of the increase in gastrin mRNA. This effect was reversed in the group (IV) receiving both octreotide LAR and ciprofibrate, resulting in a reduced somatostatin mRNA abundance (55 ± 5% of basal) compared with the control group (I) (P < 0.05) and with group II (P < 0.01). In group III, given only octreotide LAR, both somatostatin (40 ± 4% of basal) and CgA (49 ± 6% of basal) mRNA levels were significantly attenuated, compared with controls (group I) (P < 0.01). The abundances of GAPDH mRNA were unchanged in all groups compared with control.

Effects on gene expression in oxyntic mucosa
The effects on gene expression in the oxyntic mucosa are summarized in Figs 3 and 4. Ciprofibrate (group II) increased CgA (553 ± 66% of basal) and HDC (527 ± 76% of basal) mRNA abundance significantly (P < 0.001) compared with the control group (I). This increase was attenuated (P < 0.001 vs group II) in group IV receiving octreotide LAR and ciprofibrate, giving CgA
(150 ± 24% of basal) and HDC (168 ± 27% of basal) mRNA levels not significantly different from those of the control group. The somatostatin mRNA abundance in both group II (45 ± 3% of basal) and group IV (37 ± 3% of basal) was reduced compared with the control group (I) (P<0.001). In group III, receiving only octreotide LAR, the levels of CgA (32 ± 6% of basal), HDC (28 ± 3% of basal) and somatostatin (63 ± 5% of basal) mRNA were reduced compared with group I (P<0.01). The abundances of GAPDH mRNA were unchanged in all groups compared with control.

Changes in histomorphometry of antral and corpus mucosa

Changes in histomorphometry of antral mucosa are shown in Fig. 5. The number of immunoreactive G cells in the antrum was increased in all three drug groups, reaching 74% in group II, 61% in group III and 100% in group IV (all P<0.001). There were no significant differences between the four groups in the number of D cells or CgA-immunoreactive cells in antrum. Areas of immunoreactive G cells were increased 240% (P<0.01) in group II and 208% (P<0.05) in group IV compared with the control group. The area of D cells or CgA-immunoreactive cells in the antrum did not differ significantly between the four groups. Figure 6 shows examples of gastrin-immunoreactive cells in group II and IV compared with control (group I).

Changes in histomorphometry of oxyntic mucosa

Areas of CgA-immunoreactive and ECL cells in the corpus increased 130 and 327% respectively in group II, receiving ciprofibrate (P<0.001 vs. control). In group IV, receiving both drugs, the cell numbers were only 63 and 106% above the densities in the
control group \((P<0.001)\) and thus, 29 and 52\% reduced compared with group II \((P<0.001)\). In group III, dosed with octreotide LAR alone, the CgA-immunoreactive and ECL cell numbers were reduced 38\% \((P<0.05)\) and 77\% \((P<0.001)\) compared with controls. Areas of CgA-immunoreactive and ECL cells in group II increased 190 and 714\% respectively \((P<0.001 \text{ vs control})\). In group IV, receiving both drugs, the areas were reduced 49\% \((P<0.01)\) and 60\% \((P<0.05)\) compared with group II, and were not significantly higher than in the control group. Dosing with octreotide LAR alone also reduced the areas of CgA-immunoreactive and ECL cells, although not significantly. Figure 8 shows examples of HDC-immunoreactive cells in group II and IV compared with control (group I).

The area of parietal cells in the corpus, assessed by computerized image analysis, did not differ between the groups (data not shown).

---

**FIGURE 4.** Abundance of HDC mRNA, CgA mRNA and somatostatin mRNA in oxytic mucosa of control rats (group I) or rats dosed with either ciprofibrate (group II), octreotide LAR (group III) or a combination of both (group IV) for 60 days. All values are mean ± S.E.M., expressed as percent of the values in group I. **\(P<0.01\), ***\(P<0.001\) vs control or as indicated.

**FIGURE 5.** Area (A) and density (B) of gastrin-, somatostatin- and CgA-immunoreactive cells in antrum of control rats (group I) or rats dosed with either ciprofibrate (group II), octreotide LAR (group III) or a combination of both (group IV) for 60 days. All values are mean ± S.E.M. *\(P<0.05\), **\(P<0.01\), ***\(P<0.001\) vs control.

---

DISCUSSION

This study shows that ciprofibrate increases gastrin mRNA abundance, induces hypergastrinemia and increases both the number and area of G cells, suggesting a modest trophic effect on the G cells. This is consistent with previous studies, showing that ciprofibrate stimulates G cell function and slightly increases G cell density without reducing gastric acidity (Martinsen et al. 1996, Hammer et al. 1998, Waldum et al. 1998). Mild G cell hyperplasia caused by sustained achlorhydria has also been reported by others (Lundell et al. 1988, Kimura 1993), but further proliferation into G cell carcinoids is rare. Normally somatostatin from the D cells in antrum inhibits G cell function (Saffouri et al. 1980, Karnik et al. 1989, Zaki et al. 1996), and the somatostatin analog octreotide has high affinity for somatostatin receptors of subtype 2 (SSTR-2) located on G cells (Zaki et al. 1996). Still, administration of octreotide in combination with...
ciprofibrate did not reduce G cell hyperfunction compared with ciprofibrate alone, and thus this study shows no functional or antiproliferative effect of octreotide on the G cell. This is different from other studies showing that octreotide reduces both hypergastrinemia caused by acid secretory inhibition (Modlin et al. 1992, Kimura 1993) and in different pathophysiological conditions (Bordi et al. 1993, D’Adda et al. 1996). The exact mechanism by which ciprofibrate induces hypergastrinemia is not known, but the present data, together with previous results (Hammer et al. 1998), show a mechanism fundamentally different from what is found during acid suppression. It is accepted that the molecular target for the fibrates is the α-subtype of the nuclear peroxisome proliferator-activated receptor (PPAR) family (Issemann & Green 1990). The precise cellular location of this receptor in the stomach is not known, but at least in the rat it is found throughout the digestive tract (Braissant et al. 1996). Whether fibrates bind directly to PPAR-α or activate it indirectly by altering the metabolism of an unknown endogenous ligand, is still unsettled (Kliwer et al. 1999). Peroxisome proliferators, including the fibrates, are lipid soluble and cross the cell membrane to activate the nuclear receptors that act directly as transcriptional factors regulating expression of genes (Issemann & Green 1990). On the other hand, at least somatostatin and probably also antral luminal H+ ions, regulate G cells via surface receptors. These different mechanisms might explain why ciprofibrate-induced hyperfunction of the G cell is independent of both luminal pH and octreotide.

The hypergastrinemia in the group receiving ciprofibrate induced, as expected, a pronounced hypertrophy and hyperplasia of the ECL cells in oxyntic mucosa, confirmed by increases in the number and area of CgA-immunoreactive and ECL cells, HDC and CgA mRNA abundances and plasma histamine level. In the normal rat corpus, the ECL cell is the most abundant neuroendocrine cell (Sundler & Hakanson 1991), and variation in CgA parameters represents changes in the ECL cell population. The specific trophic effect exerted by gastrin on the ECL cells in group II results in an even greater dominance of the total number of neuroendocrine cells, and explains the equal densities of ECL and CgA-immunoreactive cells in this group (Fig. 5). The results are comparable with findings in other studies evaluating the trophic effects of hypergastrinemia (Ryberg et al. 1989, Brenna & Waldum 1992, Waldum et al. 1998). Comparison of the H⁺/K⁺-ATPase-immunoreactive area in corpus sections from all groups did not reveal any differences. Thus, in this study there is no indication that gastrin or octreotide affects the density of parietal cells. Administration of
octreotide in combination with ciprofibrate resulted in a pronounced decrease in all parameters representing the ECL cell population, reaching near control group levels. Since the hypergastrinemia in this group was sustained (144 pmol/l) and equal to the plasma gastrin level in group II (145 pmol/l), it seems obvious that octreotide has a direct effect on the ECL cells, reducing expression of HDC and CgA mRNA, histamine release and cellular proliferation. This is consistent with localization of the SSTR-2 on ECL cells (Borin et al. 1996), and similar suppression has been seen in other studies on both humans and rats (Cadiot et al. 1988, Modlin et al. 1992, Bordi et al. 1993, Tsutsui et al. 1995, Borin et al. 1996, D’Adda et al. 1996). However, most of these studies observed a significant reduction of plasma gastrin concentration (Modlin et al. 1992, Bordi et al. 1993, D’Adda et al. 1996) and therefore suggest that octreotide inhibits the ECL cells mainly by reversing the hypergastrinemia and not directly. Cadiot et al. (1988) observed a tendency to reduction in fundic argyrophil cell density after 70 days’ administration of the somatostatin analog SMS (201–995) and omeprazole to rats, despite unchanged plasma gastrin levels. However, to our knowledge the present work is the first long-term study that, in addition to inhibition of ECL cell function, also shows a direct antiproliferative effect of octreotide on rat ECL cells that are continuously stimulated by gastrin. This study not only shows an inhibitory effect of octreotide on the gastrin-stimulated ECL cell, but also a significant reduction of basal ECL cell function and growth, as seen in the group dosed with octreotide alone.

Contrary to previous studies (Hammer et al. 1998, Waldum et al. 1998), we found no obvious stimulating effect of ciprofibrate on the antral D cell. However, somatostatin mRNA abundance and area of D cells in group II tended to be increased, and the lack of reduction in D cell parameters accompanying the increase in G cell parameters, is alone in obvious contrast to their normal reciprocal relationship (Lundell et al. 1988, Wu et al. 1991). The lower dose of ciprofibrate in this study (50 mg/kg body weight) compared with earlier studies (100 mg/kg body weight), may explain the difference in effect on antral D cells. Ciprofibrate dosing slightly increases gastric acidity as a consequence of the hypergastrinemia (Martinsen et al. 1996), which could explain the marginal increases in somatostatin mRNA. Still, the decrease in luminal pH after ciprofibrate dosing was minute and administration of ciprofibrate together with omeprazole, which completely blocks acid secretion, did not reduce somatostatin mRNA expression. Instead it resulted in a level higher than after dosing with omeprazole alone (Hammer et al. 1998). In the present study, dosing of ciprofibrate together with octreotide, which also inhibits acid secretion, gave a significant decrease in somatostatin mRNA abundance compared with both controls and group II, given only ciprofibrate. An even more pronounced decrease in somatostatin mRNA was also seen in group III receiving octreotide alone. Evaluating these results, a direct action on the antral G and D cells still seems the most probable explanation for the effect of ciprofibrate. Whether ciprofibrate reaches these cells from the gastric lumen or via the blood has not yet been settled. In a preliminary study using vascularly perfused stomachs, there was no immediate effect on gastrin release when the peroxisome proliferator clofibrate was added to the arterial perfusate (K Iwaza & H L Waldum, unpublished observations). Since oxyntic D cells are of the closed type and do not seem to be affected, it is possible that luminal ciprofibrate acts locally on endocrine cells of the open type (Waldum et al. 1998).

The hypergastrinemic effect of ciprofibrate begins relatively late (14 days), and a continuous administration of the drug is necessary to stimulate the G cell hyperfunction. To our knowledge, there are no cell lines derived from antral G cells or other gastric endocrine cells that are functional and retain their characteristics, thus being available for long-term studies. Acute models like primary cultures of isolated G cells or ECL cells, that could have helped understand the cellular and molecular basis of ciprofibrate action, are unsuitable due to the long period of stimulation before effects can be observed. In the present study, the G cell activity increased slightly in the group receiving only octreotide. Apparently, elevated gastric luminal pH due to octreotide suppression of the oxyntic mucosa stimulates G cell function to overcome the direct inhibitory effect of octreotide. Few comparable studies have been done to measure the long-term effects of somatostatin analogs on intragastric pH, but generally previous results indicate that luminal pH and content are dominant regulators of both antral G and D cell functions (Lundell et al. 1988, Sandvik & Waldum 1988, Dimaline et al. 1991, Wu et al. 1991, Kimura 1993, Westbrook et al. 1998).

Antral CgA does not increase in parallel with G cell parameters, but instead seems to follow antral somatostatin mRNA and D cell density. This confirms other studies showing that D cells and enterochromaffin cells (EC) are the main sources of CgA in antrum and that G cells mostly contain CgB (Portela-Gomes et al. 1997). The reductions in oxyntic somatostatin mRNA in all groups with
plasma gastrin concentrations above normal are explained by the negative effect of circulating plasma gastrin, binding to CCK-B receptors on oxyntic D cells (Chen et al. 1992).

In conclusion, the present study shows that octreotide does not reverse ciprofibrate-induced hypergastrinemia, indicating that ciprofibrate stimulates antral G cells by a mechanism which, in addition to being independent of luminal pH, is unaffected by the normal suppressive action of somatostatin. This seems to be a novel mechanism, fundamentally different from other G cell-stimulating conditions in the stomach. On the other hand, the ECL cell hypertrophy and hyperplasia following ciprofibrate-induced hypergastrinemia are significantly reduced by octreotide, despite maintained stimulation by gastrin. Octreotide also has a substantial inhibitory effect on basal ECL cell function and growth. This is the first long-term study on rats that shows direct antiproliferative effects of octreotide on ECL cells independent of changes in plasma gastrin.

ACKNOWLEDGEMENTS

We thank Hege Rorvik, Bjørn Munkvold, Britt Schulze, Anne Kristensen and Gunnar Qvigstad for their technical assistance. This work was supported by The Research Council of Norway.

REFERENCES


Issermann I & Green S 1990 Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators (see comments). Nature 347 645–650.


Journal of Molecular Endocrinology (2000) 25, 109–119
Convergence of three steroid receptor pathways in the mediation of nongenotoxic hepatocarcinogenesis. 
*Carcinogenesis* 17 185–190.


Xynos E, Vassilakis JS, Neonakis E, Fountoukis A & Kittas C 1987 Alterations in serum gastrin levels and antral G- and D-cell population following corticosteroid administration. RIA and immunocytochemical long-term study in guinea pigs. *Digestion* 36 7–12.


**REVISED MANUSCRIPT RECEIVED 23 March 2000**